- Home
- LICN vs RDHL Comparison
LICN vs RDHL Comparison
Compare LICN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- RDHL
- Stock Information
- Founded
- LICN 2004
- RDHL 2009
- Country
- LICN China
- RDHL Israel
- Employees
- LICN N/A
- RDHL N/A
- Industry
- LICN
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- RDHL Health Care
- Exchange
- LICN Nasdaq
- RDHL Nasdaq
- Market Cap
- LICN 3.8M
- RDHL 3.9M
- IPO Year
- LICN 2023
- RDHL N/A
- Fundamental
- Price
- LICN $4.66
- RDHL $1.70
- Analyst Decision
- LICN
- RDHL
- Analyst Count
- LICN 0
- RDHL 0
- Target Price
- LICN N/A
- RDHL N/A
- AVG Volume (30 Days)
- LICN 84.7K
- RDHL 43.1K
- Earning Date
- LICN 01-01-0001
- RDHL 09-05-2025
- Dividend Yield
- LICN N/A
- RDHL N/A
- EPS Growth
- LICN N/A
- RDHL N/A
- EPS
- LICN N/A
- RDHL N/A
- Revenue
- LICN $41,477,000.00
- RDHL $9,550,000.00
- Revenue This Year
- LICN N/A
- RDHL $381.91
- Revenue Next Year
- LICN N/A
- RDHL N/A
- P/E Ratio
- LICN N/A
- RDHL N/A
- Revenue Growth
- LICN 4.32
- RDHL 157.62
- 52 Week Low
- LICN $2.60
- RDHL $1.06
- 52 Week High
- LICN $462.00
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- LICN 49.94
- RDHL 63.39
- Support Level
- LICN $4.59
- RDHL $1.47
- Resistance Level
- LICN $5.30
- RDHL $1.60
- Average True Range (ATR)
- LICN 0.48
- RDHL 0.09
- MACD
- LICN -0.01
- RDHL 0.04
- Stochastic Oscillator
- LICN 31.25
- RDHL 97.98
About LICN Lichen China Limited
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.